Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 637 matching trials from the live ClinicalTrials.gov search.
Conditions
Locally Advanced or Metastatic Adenoca of the Biliary Tract
Interventions
OSI-7904L, 5-Fluorouracil/Leucovorin
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
6
States / cities
Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan + 3 more
Conditions
Colorectal Cancer, Nausea and Vomiting
Interventions
aprepitant, dexamethasone, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, palonosetron hydrochloride, quality-of-life assessment
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Savannah, Georgia • Hilo, Hawaii • Harvey, Illinois + 3 more
Conditions
Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage II Colon Cancer, Stage II Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Esophageal Cancer, Pancreatic Cancer, Bile Duct Cancer, Gastric Cancer, Gall Bladder Cancer, Small Bowel Adenocarcinoma
Interventions
Bevacizumab, Dasatinib, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
Anne Noonan
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Colorectal Cancer (CRC)
Interventions
Irinotecan, 5-Fluorouracil (bolus), 5-Fluorouracil (infusional), Leucovorin calcium, CT-322, Bevacizumab, Bevacizumab Placebo (saline solution)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Tucson, Arizona • Fountain Valley, California • Riverside, California + 9 more
Conditions
Rectal Adenocarcinoma
Interventions
Chemoradiation, short course radiation therapy, mFOLFOX6, CAPOX, fluoropyrimidine +/- oxaliplatin
Other · Radiation · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Gastric Cancer
Interventions
Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD0901, 5-Fluorouracil, Capecitabine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Baton Rouge, Louisiana • Grand Rapids, Michigan + 5 more
Conditions
Colo-rectal Cancer
Interventions
Arfolitixorin, Leucovorin
Drug
Lead sponsor
Isofol Medical AB
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
18
States / cities
Gilbert, Arizona • Los Angeles, California • Newport Beach, California + 15 more
Conditions
Stage IB Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIC Esophageal Adenocarcinoma
Interventions
Paclitaxel, Carboplatin, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Radiation Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Resectable Pancreatic Cancer
Interventions
Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable, -Oxaliplatin 85 mg/m2 IV on Day 1, -Irinotecan 180 mg/m2 IV on Day 1, -5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours
Other · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Pancreatic Cancer
Interventions
neoadjuvant mFOLFIRINOX, Stereotactic body radiotherapy (SBRT)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Advanced Cancers
Interventions
Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
Interventions
Bevacizumab, Capecitabine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, Radiation Therapy, Therapeutic Conventional Surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
107
States / cities
Birmingham, Alabama • New Britain, Connecticut • Atlanta, Georgia + 66 more
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, semaxanib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
26
States / cities
Montgomery, Alabama • Arcadia, California • La Jolla, California + 22 more
Conditions
Advanced Solid Tumors, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
Interventions
BKM120, mFOLFOX6
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Advanced Solid Tumors
Interventions
M3T01, Pembrolizumab, Chemoradiation, FOLFOX regimen
Drug · Radiation
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
Interventions
Vatalanib
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
145
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 123 more
Conditions
Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
Interventions
BOLD-100 +/- FOLFOX Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
Drug
Lead sponsor
Bold Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Santa Monica, California • Tampa, Florida
Completed Phase 3 Interventional Results available

A Study in Second Line Metastatic Colorectal Cancer

NCT01183780
Conditions
Colorectal Cancer
Interventions
Ramucirumab, Placebo, Irinotecan, Folinic Acid, 5-Fluorouracil
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
92
States / cities
Sedona, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 89 more
Conditions
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Interventions
Anvumetostat, Gemcitabine, Nab-paclitaxel, Modified FOLFIRINOX, RMC-6236
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
29
States / cities
Bakersfield, California • Duarte, California • La Jolla, California + 24 more
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, levamisole hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,917 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2008
U.S. locations
35
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 29 more
Conditions
Colorectal Cancer
Interventions
bevacizumab, fluorouracil, leucovorin calcium, oxaliplatin
Biological · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Colorectal Cancer
Interventions
bevacizumab, fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma
Interventions
Idelalisib, Nab-paclitaxel, mFOLFOX6
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 6 more
Conditions
Colorectal Cancer
Interventions
Arsenic trioxide, Fluorouracil, Leucovorin calcium, Plasma levels of elemental arsenic, Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis, Tumor Biopsy (Fine-Needle Aspiration)
Drug · Other · Genetic + 1 more
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Miami, Florida